Eric J Lehrer1, Heather M McGee2, Jason P Sheehan3, Daniel M Trifiletti4. 1. Department of Radiation Oncology, Icahn School of Medicine At Mount Sinai, 1184 5th Avenue, 1st floor, New York, NY, USA. Eric.Lehrer@mountsinai.org. 2. Department of Radiation Oncology, Icahn School of Medicine At Mount Sinai, 1184 5th Avenue, 1st floor, New York, NY, USA. 3. Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA. 4. Departments of Radiation Oncology and Neurological Surgery, Mayo Clinic, Jacksonville, FL, USA.
Abstract
AIM: Brain metastases traditionally carried a poor prognosis with treatment being a combination of surgery, whole-brain radiation therapy, and glucocorticoids; however, this treatment paradigm carried a significant amount of morbidity. In recent years, stereotactic radiosurgery (SRS), which involves the delivery of a highly conformal dose of radiation over a single session, has been shown to be an effective alternative to WBRT with excellent rates of local control and improved quality of life; however, a survival benefit has not been demonstrated. Recent developments have challenged the traditional view of the central nervous system being "immunologically privileged" which has led to a greater focus on treating these patients with systemic therapies. Immune checkpoint inhibitors (ICI) have been shown to improve survival in multiple malignancies. As a result, there has been increased utilization in combining these therapies in this setting. METHODS: We conducted a literature search of medical databases (e.g. PubMed) for articles involving the use of immune checkpoint inhibitors and stereotactic radiosurgery in managing brain metastases. RESULTS: Published evidence utilizing SRS and ICI is largely limited to single institution and retrospective in nature with the most common histology being melanoma. CONCLUSION: Combination therapy with SRS and ICI appears to improve survival in patients with brain metastases. The available data are largely retrospective; therefore, ongoing and planned prospective studies are needed to further validate these findings.
AIM: Brain metastases traditionally carried a poor prognosis with treatment being a combination of surgery, whole-brain radiation therapy, and glucocorticoids; however, this treatment paradigm carried a significant amount of morbidity. In recent years, stereotactic radiosurgery (SRS), which involves the delivery of a highly conformal dose of radiation over a single session, has been shown to be an effective alternative to WBRT with excellent rates of local control and improved quality of life; however, a survival benefit has not been demonstrated. Recent developments have challenged the traditional view of the central nervous system being "immunologically privileged" which has led to a greater focus on treating these patients with systemic therapies. Immune checkpoint inhibitors (ICI) have been shown to improve survival in multiple malignancies. As a result, there has been increased utilization in combining these therapies in this setting. METHODS: We conducted a literature search of medical databases (e.g. PubMed) for articles involving the use of immune checkpoint inhibitors and stereotactic radiosurgery in managing brain metastases. RESULTS: Published evidence utilizing SRS and ICI is largely limited to single institution and retrospective in nature with the most common histology being melanoma. CONCLUSION: Combination therapy with SRS and ICI appears to improve survival in patients with brain metastases. The available data are largely retrospective; therefore, ongoing and planned prospective studies are needed to further validate these findings.
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel Journal: N Engl J Med Date: 2015-05-31 Impact factor: 91.245
Authors: Paul D Brown; Karla V Ballman; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Anthony C Whitton; Jeffrey Greenspoon; Ian F Parney; Nadia N I Laack; Jonathan B Ashman; Jean-Paul Bahary; Costas G Hadjipanayis; James J Urbanic; Fred G Barker; Elana Farace; Deepak Khuntia; Caterina Giannini; Jan C Buckner; Evanthia Galanis; David Roberge Journal: Lancet Oncol Date: 2017-07-04 Impact factor: 41.316
Authors: Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245
Authors: Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Nils D Arvold; Eudocia Q Lee; Minesh P Mehta; Kim Margolin; Brian M Alexander; Nancy U Lin; Carey K Anders; Riccardo Soffietti; D Ross Camidge; Michael A Vogelbaum; Ian F Dunn; Patrick Y Wen Journal: Neuro Oncol Date: 2016-08 Impact factor: 12.300
Authors: Betsy A Kohler; Elizabeth Ward; Bridget J McCarthy; Maria J Schymura; Lynn A G Ries; Christie Eheman; Ahmedin Jemal; Robert N Anderson; Umed A Ajani; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2011-03-31 Impact factor: 13.506
Authors: Eric J Lehrer; Brianna M Jones; Daniel R Dickstein; Sheryl Green; Isabelle M Germano; Joshua D Palmer; Nadia Laack; Paul D Brown; Vinai Gondi; Jeffrey S Wefel; Jason P Sheehan; Daniel M Trifiletti Journal: Front Oncol Date: 2022-06-30 Impact factor: 5.738
Authors: Eric J Lehrer; Henry Ruiz-Garcia; Anthony D Nehlsen; Kunal K Sindhu; Rachel Sarabia Estrada; Gerben R Borst; Jason P Sheehan; Alfredo Quinones-Hinojosa; Daniel M Trifiletti Journal: Biology (Basel) Date: 2022-01-26
Authors: Eric J Lehrer; Arpan V Prabhu; Kunal K Sindhu; Stanislav Lazarev; Henry Ruiz-Garcia; Jennifer L Peterson; Chris Beltran; Keith Furutani; David Schlesinger; Jason P Sheehan; Daniel M Trifiletti Journal: Biomedicines Date: 2021-01-03
Authors: Montserrat Lara-Velazquez; Jack M Shireman; Eric J Lehrer; Kelsey M Bowman; Henry Ruiz-Garcia; Mitchell J Paukner; Richard J Chappell; Mahua Dey Journal: Front Oncol Date: 2021-05-11 Impact factor: 6.244